Presidio News

Presidio is developing NRTIs against common reverse transcriptase mutations.

Presidio is quickly making inroads into the development of new medicines.

04.14.08
BioCentury Emerging Company Profile -  Presidio: Penultimate NRTIs

03.20.08
Presidio Obtains Rights to XTL Biopharmaceuticals' HCV NS5A Program

02.11.08
Presidio and Numerate, Inc. Announce Research Collaboration

1.07.08
Leo Redmond Joins Presidio Pharmaceuticals as Chief Financial Officer

12.05.07
Presidio Relocates Headquarters to Mission Bay, San Francisco

09.18.07
Presidio Adds Industry Veteran Colonno as Chief Scientific Officer

08.29.07
Presidio Closes $26 Million Series B Financing

07.27.07
San Francisco Business Times: Startup Takes Aim at AIDS

06.22.07
Presidio Announces Key Executive Management Additions

01.16.07
Presidio Receives Exclusive License to Novel HCV Technology from Stanford

01.09.07
Presidio Licenses Nuclear Exclusion Compounds from Cytokine Pharmasciences

12.20.06
Medivir Outlicenses Antivirals Alovudine (MIV-310) and MIV-410 to Presidio